drugset / Trial / NCT06108492

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

NCT06108492

Phase 1 Recruiting 170 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in patients with intermediate and high-risk non-muscle invasive bladder cancer.

Timeline

Start
2023-11-28
Primary completion
2026-12-31
Completion
2027-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-2005 Unknown Other